05:10 AM EST, 11/19/2025 (MT Newswires) -- GSK (GSK) and LTZ Therapeutics said Wednesday they will collaborate on developing up to four potential novel myeloid cell engagers that target haematologic cancers and solid tumors.

The deal will give GSK an exclusive option to license global development and commercial rights for the pre-clinical therapies.

LTZ will receive an upfront payment of $50 million, plus potential milestone payments and royalties on net sales, the companies said.